Immunological monitoring for prediction of clinical response to antitumor vaccine therapy
Metrics: PDF 925 views | HTML 1641 views | ?
Irina N. Mikhaylova1, Irina Zh. Shubina1, George Z. Chkadua1, Natalia N. Petenko1, Lidia F. Morozova1, Olga S. Burova1, Robert Sh. Beabelashvili2, Kermen A. Parsunkova3, Natalia V. Balatskaya4, Dmitrii K. Chebanov5, Vadim I. Pospelov6, Valeria V. Nazarova1, Anastasia S. Vihrova1, Evgeny A. Cheremushkin1, Alvina A. Molodyk1, Mikhail V. Kiselevsky1 and Lev V. Demidov1
1N.N. Blokhin Russian Cancer Research Center, Moscow, Russia
2Laboratory of Genetic Engineering, Institute of Experimental Cardiology, Russian Cardiological Research and Production Complex, Moscow, Russia
3Diagnostic Laboratory Clinical Center “Optimum”, Sochi, Russia
4Department of Immunology and Virology, Moscow Helmholtz Research Institute of Eye Diseases, Moscow, Russia
5RUDN University, Moscow, Russia
6“Genetic Technologies and Analyses”, Moscow, Russia
Irina Zh. Shubina, email: email@example.com
Keywords: cancer vaccine therapy; melanoma; predictive markers; B2-microglobulin
Received: September 04, 2017 Accepted: March 22, 2018 Published: May 11, 2018
Immunotherapy has shown promising results in a variety of cancers, including melanoma. However, the responses to therapy are usually heterogeneous, and understanding the factors affecting clinical outcome is still not achieved. Here, we show that immunological monitoring of the vaccine therapy for melanoma patients may help to predict the clinical course of the disease.
We studied cytokine profile of cellular Th1 (IL-2, IL-12, IFN-γ) and humoral Th2 (IL-4, IL-10) immune response, vascular endothelial growth factor (VEGFA), transforming growth factor-β 2 (TGF-β 2), S100 protein (S100A1B and S100BB), adhesion molecule CD44 and serum cytokines β2-microglobulin to analyze different peripheral blood mononuclear cell subpopuations of patients treated with dendritic vaccines and/or cyclophosphamide in melanoma patients in the course of adjuvant treatment.
The obtained data indicate predominance of cellular immunity in the first adjuvant group of patients with durable time to progression and shift to humoral with low cellular immunity in patients with short-term period to progression (increased levels of IL-4 and IL- 10). Beta-2 microglobulin was differentially expressed in adjuvant subgroups: its higher levels correlated with shorter progression-free survival and the total follow-up time. Immunoregulatory index was overall higher in patients with disease progression compared to the group of patients with no signs of disease progression.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.